Information Provided By:
Fly News Breaks for January 13, 2020
Jan 13, 2020 | 07:05 EDT
H.C. Wainwright analyst Edward White raised his price target for Syndax to $17 from $15 after the company provided a strategic outlook for 2020 and anticipated milestones. Management stated that the upcoming final overall survival analysis for E2112 is still expected in Q2 of 2020 after 410 deaths from the 608 patients enrolled in the trial have occurred, White tells investors in a rehears note. He reiterates a Buy rating on Syndax.
News For SNDX From the Last 2 Days
There are no results for your query SNDX